Design Therapeutics, Inc.
DSGN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.26 | -0.11 | -1.47 | -0.61 |
| FCF Yield | -7.58% | -7.70% | -2.82% | -3.13% |
| EV / EBITDA | -8.02 | -10.25 | -19.92 | -17.20 |
| Quality | ||||
| ROIC | -10.03% | -8.84% | -6.81% | -6.35% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.66 | 0.76 | 0.95 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 13.84% | -71.00% | -3.46% | 16.56% |
| Safety | ||||
| Net Debt / EBITDA | 0.86 | 0.57 | 1.22 | 1.73 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -599.80 | -1,800.00 | -1,127.09 | -864.71 |